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1. Introduction  
Acute pancreatitis is the third most common gastrointestinal disease diagnosis at hospital 
discharge. (Browse 2003) Although many etiologies exist, the most common causes 
worldwide are gallstone disease and excessive alcohol consumption. However, one-third of 
pancreatitis cases have no association with alcohol, no associated biliary tract disease, and 
no pancreatic duct obstruction, and are thus labelled idiopathic. Despite a documented 
increase in the overall incidence of acute pancreatitis in several countries, disease related 
mortality has progressively declined over the years. This improvement is in part due to 
advances in disease management, including better diagnostics and treatment modalities. 
(Baron 2001) 
Acute pancreatitis is a pathological condition in which activated pancreatic enzymes leak 
into the substance of the pancreas and initiate  auto-digestion of the gland. Most episodes of 
acute pancreatitis are mild and self-limiting and do not require aggressive intervention. In 
marked contrast, approximately one fifth of patients develop severe acute pancreatitis 
which is associated with a mortality rate that can exceed 30%. (Bradley and Dexter 2010).  
Pancreatitis occurs with equal frequency in men and women, despite the common 
association of gallstones  with female gender. Although the peak incidence of pancreatitis is 
in the fourth and fifth decades of life, it  can occur at any age.  
2. Signs and symptoms 
The most common presenting symptom of acute pancreatitis is pain. Typically the 
discomfort begins suddenly, high in the epigastrium, and steadily increases in severity until 
movement is intentionally limited and respiratory excursion is reduced. It is often 
unrelenting and may radiate through to the back, classically just to left of mid-line. 
Frequently, a complex of nausea, vomiting and retching accompanies the abdominal pain. 
Although many acute abdominal conditions can cause nausea, and vomiting, pancreatitis is 
often associated with a specific pattern of persistent nausea between cyclical bouts of emesis 
without nausea prior to initiation of the pain. (Mergener and Baillie 1998) 
Many patients report having eaten an unusually large meal or drunk alcohol an hour or so 
before the pain began (Mergener and Baillie 1998). When the pain is severe, any movement 
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of the lower chest wall and abdomen exacerbates the discomfort, often resulting in  rapid 
shallow breathing and a sensation of dyspnea. In advanced cases, patients may develop 
tetanic muscle twitches, cramps and spasms related to associated hypocalcemia associated 
with the development of intra-abdominal fat necrosis. (Browse 2003) 
As the condition progresses, retroperitoneal inflammation and trans-capillary leak reduce 
intravascular volume resulting in tachycardia with peripheral vasoconstriction generating a 
pale skin tone and diaphoresis. A paralytic intestinal ileus may develop, resulting in 
abdominal distension, a quiet abdomen to auscultation, and aggravation of nausea. 
Advanced cases may be associated with retroperitoneal haemorrhage, causing bruising and 
discoloration in the left flank (Grey Turner’s sign) and around the umbilicus (Cullen’s sign); 
both are late signs of extensive inflammatory destruction of the pancreas and peri-pancreatic 
tissues. (Dickson et al 1984) 
Physical findings often consist of tenderness to palpation in the upper abdomen and 
abdominal distension, with severe cases producing diffuse abdominal guarding with 
discrete epigastric fullness secondary inflammatory exudate present in the lesser sac. Over 
time, this collection can organize, resulting in the formation of a pancreatic pseudocyst or 
lesser sac abscess. (Browse 2003) 
3. Laboratory assessment, risk assessment and prognostic systems 
Multiple risk assessment and classification systems have been developed over the years to 
assist in the clinical assessment of patients presenting with acute pancreatitis. These systems 
have been formulated in an attempt to predict the severity of a given episode of pancreatitis, 
and therefore aid in directing disease- appropriate management plans. Notable tools include 
the Atlanta Classification, Ranson’s Criteria, the Acute Physiology and Chronic Health 
Evaluation (APACHE) II systems, and the Balthazar CT Severity Index (CTSI). (Brisinda, 
Vanella et al. 2011) 
3.1 Biochemical values used for prognostication 
Biochemical markers, including serum amylase and lipase, have been traditionally utilized 
in the diagnosis of acute pancreatitis. Newer indices have been reported to yield higher 
correlations with the presence of pancreatitis and have demonstrated improved prognostic 
value. (Gates 1999) 
3.1.1 Serum amylase and lipase 
Serum amylase and lipase levels are the most commonly obtained biochemical markers of 
pancreatic disease, particularly for evaluation of the presence of acute pancreatitis. However, 
the utility of these enzyme markers is complicated by significant limitations, including low 
sensitivity and specificity (Young 1989). In aggregate, there are many causes of elevated serum 
amylase levels, and amylase levels may only be moderately elevated or even normal in proven 
cases of acute pancreatitis of all degrees of severity (Clavien et al. 1989).  
While an amylase level of three times the upper limit of normal is often recommended to 
support a clinical diagnosis of acute pancreatitis, the magnitude of the observed 
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hyperamylasemia has limited direct correlation with disease severity (Clavien et al. 1989). 
Furthermore, after reaching a peak serum concentration, the subsequent return of amylase 
levels to previously normal levels does not necessarily correlate with resolution of clinical 
illness, limiting the value of serial measurements (Young 1989). If hyperamylasemia 
temporally persists in conjunction with clinical symptoms, consideration should be given to 
the presence of a pseudocyst or peri-pancreatic abscess. Clinical studies have demonstrated 
that serum amylase levels can be normal in one-fifth of diseased patients, elevated in one-
quarter of well patients, and that the magnitude of serum elevation has poor statistical 
correlation with disease severity or ultimate prognosis. (Vissers, Abu-Laban et al. 1999) 
Serum lipase is the acinar enzyme most often recommended to replace or supplement 
amylase levels for the diagnosis of acute pancreatitis. At a cut-off of five times the upper 
limit of normal, an elevated lipase is virtually diagnostic for pancreatitis, approaching 100% 
specificity; however, its sensitivity is limited to 60% (Kazmierczak et al. 1993). Given these 
considerations, using a multiple of twice the upper limit of normal may offer high specificity 
without significantly compromising sensitivity. Although few studies have examined the 
prognostic value of elevated lipase levels in acute pancreatitis, most suggest poor correlation 
with disease severity, similar to amylase. (Vissers, Abu-Laban et al. 1999) 
Simultaneous measurements of both serum lipase and amylase have not been shown to 
improve diagnostic accuracy, and no advantage has been demonstrated over assaying lipase 
alone (Viel et al. 1990). While serum lipase measurements are comparable to amylase in 
terms of speed, cost, and availability, evidence suggests that lipase is the more accurate 
assay for acute pancreatitis (Clave et al. 1995). As a result, in institutions where both tests 
are available, it is recommended that lipase replace amylase as the initial enzymatic test for 
acute pancreatitis. Regardless of the marker employed, it is important to appreciate that the 
absolute levels of neither amylase nor lipase have prognostic value in established disease. 
(Vissers, Abu-Laban et al. 1999) 
3.1.2 Blood Urea Nitrogen (BUN) 
Some studies have demonstrated that an elevated Blood Urea Nitrogen (BUN) level at 
admission and subsequent temporal increases in BUN levels during the initial 24 hours of 
hospitalization are independent risk factors for mortality in acute pancreatitis (Wu et al. 
2009). Serial BUN measurements have also been shown to provide prognostic accuracy 
comparable to the more complex APACHE II score for early prediction of in-hospital mortality 
(Papachristou et al. 2010). Among patients with an elevated BUN value at admission (>20 
mg/dL), a decrease of at least 5 mg/dL at 24 hours is associated with a reduced risk of in-
hospital death. In contrast, among patients with a normal BUN value at admission, even 
modest increases in the BUN level (≥ 2mg/dL) are associated with an increased risk of 
mortality (Wu, Bakker et al. 2011). Due to its correlation with outcome, an algorithm based on 
early changes in BUN level has been developed to aid clinicians in evaluating patient 
responses to early resuscitation efforts in pancreatitis. (Wu, Bakker et al. 2011) 
3.1.3 Coagulation parameters: D-dimer and tissue factor 
Coagulation disorders are known to occur in the early phase of severe acute pancreatitis and 
the D-dimer of fibrinogen is a commonly used clinical parameter to assess the hemostatic 
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system (Salomone et al. 2003). Studies have demonstrated that serum D-dimer levels 
significantly differ between pancreatitis patients with and without key clinical 
differentiators such as the progression to multiple organ dysfunction syndromes, the 
eventual need for surgical intervention, and the development of both pancreatic and 
secondary infection (Radenkovic et al. 2009). Furthermore, serum D-dimer levels have been 
demonstrated to correlate well with two traditional markers of severity in acute pancreatitis, 
namely the APACHE II score and C-reactive protein serum levels (Papachristou, Whitcomb 
2004). As such, the D-dimer assay may be a useful, easy, and inexpensive early prognostic 
marker of the evolution and complications of acute pancreatitis. (Ke, Ni et al. 2011) Several 
studies have demonstrated elevated levels of circulating Tissue factor (TF) to be present in 
patients presenting with acute pancreatitis (Yasuda et al. 2009). Furthermore, a weak 
statistical correlation between assayed serum TF levels and disease severity has been 
observed (Yasuda et al. 2009).  Further studies will be required to characterize this 
relationship. (Andersson, Axelsson et al. 2010)  
3.1.4 C-reactive protein (CRP) 
C-reactive protein (CRP) is an acute phase reactant that is elevated in several inflammatory 
conditions and serves as a non-specific marker for inflammation (Wilson et al 1989). In acute 
pancreatitis, CRP levels commonly peak on the 3rd or 4th day after symptom onset, with 48-
hour values of 150 mg/dL often accepted as a predictor of subsequent disease severity 
(Dervenis et al. 1999). It has been demonstrated that peak CRP levels of ≥210 mg/dL can 
differentiate severe acute pancreatitis from milder forms with a sensitivity of 83-84% and a 
specificity of 74-85%. (Wilson et al. 1989) Similar studies have shown that high CRP levels 
have an overall accuracy of 93% in detecting pancreatic necrosis. CRP levels are easy to 
measure, widely available, and relatively inexpensive to perform. One disadvantage of CRP 
is its delayed serum peak (48-72 hours), although this delay is also inherent in other 
methods used for severity assessment in acute pancreatitis such as the Ranson criteria. 
(Yadav, Agarwal et al. 2002) 
3.1.5 Hemoconcentration 
Recently, hemoconcentration has been identified as a strong risk factor and an early marker 
for the develpment of necrotizing pancreatitis and organ failure (Baillargeon, Ramagopal et 
al. 1998). Admission hematocrit (Hct)  ≥ 47 and failure of admission Hct to decrease by 24 h 
represent strong risk factors for the development of severe pancreatitis. (Yadav, Agarwal et 
al. 2002). The sensitivity of hematocrit as a marker for necrotizing pancreatitis is 72% at 
admission and increases to 94% at 24 hours; specificity is 83 and 69%, respectively. 
(Baillargeon, Ramagopal et al. 1998) 
The relationship between hemoconcentration and the development of pancreatic necrosis 
has been studied extensively in experimental animal models (Hotz et al. 1995). These studies 
have shown that early hemoconcentration in acute pancreatitis contributes significantly to 
the impairment of the pancreatic microcirculation and to the subsequent progression to 
pancreatic necrosis (Hotz et al. 1995). Patients presenting with an elevated admission 
hematocrit or those demonstrating an admission hematocrit that does not decrease by 24 
hours are at high risk for complications (Brown, Orav et al. 2000). Consideration in this 
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patient cohort should be given to early intensive care unit admission for vigorous fluid 
resuscitation, supportive care, and continous hemodynamic monitorring. In contrast, 
patients who do not exhibit these criteria may have a lower likelihood of developing severe 
pancreatitis and could represent a group that requires less intensive care. (Brown, Orav et al. 
2000) 
3.1.6 Interleukins and procalcitonin 
Interleukins, particularly IL-6 and IL-8, have been identified as serum markers of disease 
severity in acute pancreatitis (Heath et al. 1993 and Rau et al 1997). Although predictive 
accuracies have varied in several clinical studies, meta-analyses performed to assess their 
utility in predicting severe acute pancreatitis have demonstrated promising correlations. 
(Gregoric, Sijacki et al. 2010) 
IL-6 is a cytokine produced by a wide variety of cell types, including macrophages (Xing et 
al 1994). It drives the hepatic acute phase response and as such may be one biochemical step 
closer than CRP to the underlying inflammatory process in acute pancreatitis. Serum levels 
of IL-6 in patents with severe pancreatitis can be elevated as early as five hours after 
admission; pooled sensitivities range between 81.0% and 83.6%, specificities between 75.6 
and 85.3%, and odds ratios of between 3. 43 and 4.90 in predicting disease severity (Aoun, 
Chen et al. 2009). IL-8 serum levels also have been found to correlate with pancreatitis, with 
pooled sensitivities identified between 65.8 and 70.9% and specificities of 66.5% and 91.3% 
for days 1 and 2 of disease presentation. (Aoun, Chen et al. 2009) 
Procalcitonin (PCT) is the inactive propeptide of the hormone calcitonin, which is involved 
in calcium homeostasis (Assicot et al. 1993). In patients with acute pancreatitis, PCT has 
been shown to predict the subsequent development of infected pancreatic necrosis and has 
been demonstrated to be a predictor of severity and organ failure in patients with acute 
pancreatitis (Riche et al. 2003). Sensitivity analyses performed on multiple studies have 
demonstrated that a serum PCT value greater than 0.5 ng/mL is an accurate predictor of 
severe acute pancreatitis (Mofidi, Suttie et al. 2009). In studies where daily serum PCT levels 
were measured, it was noted that patients who subsequently developed infected pancreatic 
necrosis had a sustained increase in serum PCT levels and that the degree of PCT increase 
reflected the severity of systemic inflammation and progresion to multiorgan dysfunction 
(Rau et al. 1997). Furthermore, it has been observed that serum PCT levels tend to decrease 
with clinical improvment (Rau et al. 1997).  
The identification of pancreatic necrosis is clinically important because patients with sterile 
pancreatic necrosis are often treated with supportive care only, whereas infected pancreatic 
necrosis generally requires surgical or radiologic intervention (Büchler et al. 2000). Infected 
pancreatic necrosis is classically diagnosed by microbial culture of material obtained using 
image-guided FNA of pancreatic tissue. Unlike FNA, the measurement of PCT is non-
invasive and is not hindered by the potential for image-directed sampling error. 
Furthermore, PCT levels are not affected by antifungal and antimicrobial systemic coverage, 
and remain elevated in infected pancreatic necrosis (Rau et al. 1997). However, it is 
important to note that PCT is a nonspecific marker of infectious complications in critically ill 
patients, and as a result other infective foci need to be excluded carefully when interpreting 
PCT measurements in pancreatitis.. (Mofidi, Suttie et al. 2009) 
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3.2 Systems based risk models 
3.2.1 Atlanta classification 
Most recent attempt to standardize severity criteria in acute pancreatitis The 1992 Atlanta 
Symposium was convened to standardize severity criteria and nomenclature in acute 
pancreatitis (Bradley 1993). A major step forward at the time was the establishment of a 
universal definition of severe pancreatitis. Objective criteria of severity and outcome were 
defined by both local and systemic parameters (Table 1.) In addition, universal standards to 
define “predicted severe” pancreatitis were adopted based on the two most popular scoring 
systems, namely the Ranson criteria and the Acute Physiology and Chronic Health 
Evaluation II (APACHE II) criteria. “Predicted severe” pancreatitis was defined as either a 
score of three or more in Ranson criteria, or eight or more in APACHE-II criteria.  
(Gates 1999)  
Severity Criteria  Definitions 
  
Organ Failure  
Cardiovascular Systolic blood pressure < 90 mm Hg ( after resuscitation ) 
Respiratory PaO2 < 60mmHg ( 8 kPa ) 
Renal Serum creatinine > 177 µmol/l ( 2mg/dl ) after resuscitation 
Gastrointestinal 
Haemorrhage 
>500 ml/ 24h 
  
Systemic 
Complications 
 
Coagulation 
System 
Platelet count < 100 × 109/l  
 Fibrinogen level < 1g/l 
 Fibrin split products >80µg/mL 
Metabolic Corrected serum calcium < 1.85 mmol/l ( 7.5 mg/dl)  
serum lactate levels > 5mmol/l 
  
Local Complications  
Acute fluid 
collections 
Occur early in the natural history of acute pancreatitis and lack a 
fibrous capsule 
Pseudocyst Occurs at least 4 weeks after the onset of symptoms and has a fibrous 
capsule 
Pancreatic abscess A localised collection of pus containing little or no necrotic pancreatic 
material  
Pancreatic necrosis Pathological features : diffuse or focal area of nonviable pancreas that 
maybe associated with peripancreatic fat necrosis CT features : an 
area of non-enhancing pancreas measuring > 3 cm in diameter or 30% 
of pancreatic tissue  
Table 1. Atlanta Classification for Severe Pancreatitis 
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Threshold scores for assignment of “predicted severe” pancreatitis 
≥ 3 Ranson criteria 
≥ 8 APACHE II criteria 
Although the Atlanta Classification has proven useful, a more thorough classification 
system could incorporate assessment of clinical severity with more objective measurements 
of anatomic pathology in and around the pancreas. In addition, the Atlanta Classification 
fails to differentiate between the two discrete peaks in mortality (early and late) observed 
with pancreatitis. (Brisinda, Vanella et al. 2011) 
3.2.2 Ranson criteria 
Ranson proposed the first numerical grading system for acute pancreatitis in 1974, focusing 
on several commonly observed clinical and hematochemical variables (Ranson et al. 1974). 
With an increased number of risk factors present, there is a corresponding increase in 
mortality rate (Ranson et al. 1974). In patients with less than three positive signs no 
significant associated mortality is observed, whereas in patients with at least six signs the 
mortality rate is over 50% (Ranson 1995). Furthermore, individuals with a score greater than 
six often develop necrotising pancreatitis (Ranson 1995). This system is particularly useful at 
the two extremes of the scale, with less discriminating power between; correlation with 
severity of disease or the eventual development of necrosis in patients with a score of 3-5 is 
deficient. (Brisinda, Vanella et al. 2011) 
 
At admission During initial 48 hours 
Age > 55 years Hematocrit decrease > 10% 
White blood cell count > 16000/µl Blood urea nitrogen increase >5mg/dl  
( >1.8 mmol/l) 
Serum glucose level > 200 mg/dl  
(>11.1 mmol/l) 
Calcium < 8 mg/dl (<2 mmol/l) 
Serum lactate dehydrogenase > 350 IU/l PaO2 < 60 mmHg 
Aspartate Aminotransferase > 250 IU/l Base deficit > 4 mEq/l 
 Fluid sequestration > 6 l 
Table 2. Ranson criteria for non- gallstone pancreatitis 
 
At admission During initial 48 hours 
Age > 70 years Hematocrit decrease > 10% 
White blood cell count > 18000/µl Blood urea nitrogen increase >5mg/dl  
( >1.8 mmol/l) 
Serum glucose level > 220 mg/dl  
(>12.2 mmol/l) 
Calcium < 8 mg/dl (<2 mmol/l) 
Serum lactate dehydrogenase > 400 IU/l PaO2 < 60 mmHg 
Aspartate Aminotransferase > 250 IU/l Base deficit > 5 mEq/l 
 Fluid sequestration > 4 l 
Table 3. Ranson criteria for gallstone pancreatitis 
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The Ranson scoring system was derived from statistical analysis of multiple clinical and 
laboratory parameters from consecutive patients who were tested for significant correlation 
with disease outcome (Ranson et al. 1974). The result was an 11-point conglomerate of 
predictive factors, five of which were to be obtained on admission and the remaining six 
within 48 hours of presentation. Because the first group of patients analysed had a 
preponderance of alcohol-associated disease, a second analysis was later performed with 
patients manifesting gallstone pancreatitis. (Ranson et al. 1974) Thus, two separate Ranson 
criteria currently exist for gallstone and non-gallstone pancreatitis, as illustrated above. 
The Ranson scoring system has important merits, along with some deficits. Clear benefits 
include its ease of use and its clinical correlation, with an estimated sensitivity of 72%, 
specificity of 76%, positive predictive value of 51%, and negative predictive value of 89. 
(Gates 1999) 
However, many physicians inappropriately apply the non-gallstone criteria to patients with 
gallstone pancreatitis, which accounts for a third of all cases of acute pancreatitis. 
Furthermore, patients are often incorrectly classified as having “predicted mild” pancreatitis 
before 48 hours; using the Ranson criteria, patients may only be classified as “predicted 
severe” or “pending” pancreatitis before the 48 hour mark. Importantly, the Ranson criteria 
have not been validated for continued temporal monitoring of the patient’s condition. A 
repeat assessment with the criteria at say, 72 hours, cannot be accurately interpreted with 
the tool. It is also important to note that the Ranson criteria have not been validated for used 
in children. (Gates 1999) 
3.2.3 Glasgow criteria 
The Glasgow criteria (Imrie) were originally introduced in the late 1970’s and early 
1980’sand have since been modified three times. (Imrie et al. 1978). The original Glasgow, or 
modified system, has been used for the prediction of mortality, and like the Ranson, 
performs well. It yields an estimated sensitivity of 63%, specificity of 84%, positive 
predictive value of 52%, and negative predictive value of 89% (Steinberg 1990). When  
Variables for the Glasgow Scoring System 
Age > 55 years 
White blood cell count > 15000 /µl 
PaO2 < 60 mmHg (8 kPa) 
Serum lactate dehydrogenase > 600 units/l 
Serum aspartate aminotransferase > 200 units/la 
Serum albumin < 32g/l 
Serum calcium < 2 mmol/l 
Serum glucose > 10 mmol/l 
Serum urea > 16 mmol/l 
a Removed from revised Glasgow outcome score.  
Each variable has a binary score of 0 or 1. The outcome score is derived from the sum of all variables at 
48 hours after presentation.  
Table 4. Glasgow (Imrie) severity scoring system for acute pancreatitis  
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Table 5. Continued  
www.intechopen.com
  
Chronic Health Points: If the patient has a history of severe organ system insuffiency or is immunocompromis
points as follows: 
2 points for nonoperative or emergency postoperative patients 
2 points for elective postoperative patients 
Liver insufficiency: Biopsy proven cirrhosis; Documented portal hypertension; Episodes of past upper GI bleed
hypertension; Prior episodes of hepatic failure / encephalopathy / coma. Cardiovascular: New York Heart Ass
Respiratory: Chronic restrictive, obstructive or vascular disease resulting in severe exercise restriction, i.e. unab
household duties; Documented chronic hypoxia, hypercapnia, secondary polycythemia, severe pulmonary hyp
respirator dependency. Renal: Receiving chronic dialysis. Immunosuppression: The patient has received therapy t
infection e.g. immunosuppression, chemotherapy, radiation, long term or recent high dose steroids, or has a dis
advanced to suppress resistance to infection, e.g. leukemia, lymphoma, AIDS.  
Table 5. Acute Physiology and Chronic Health Evaluation II (APACHE-II) Worksheet Adapted from
829. (Knaus, Draper et al. 1985) 
w
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compared to Ranson, it may be less sensitive while adding increased specificity. Any 
Glasgow data point may be scored at any time during the first 48 hours of presentation, but 
like Ranson, the Glasgow system is not valid for repeat measurements beyond 48 hours and 
cannot be applied to children (Gates 199). During the initial 48 hours, a patient may be 
classified only as having “severe” or “pending” pancreatitis. (Gates 1999) 
3.2.4 Acute Physiology and Chronic Health Evaluation II (APACHE-II) 
The Acute Physiology and Chronic Health Evaluation II (APACHE-II) assessment has 
become popular more recently. The system is comparatively complex and more difficult to 
perform because 12 different physiologic measurements are used (Larvin 1989). The higher 
the total score, the more severe the episode of acute pancreatitis, which corresponds to an 
increase in predicted morbidity and mortality (Wilson et al. 1990). One major advantage of 
the APACHE-II numeric system compared with other systems is that it can be used 
throughout the patient’s hospital course, aiding evaluation and monitoring of response to 
therapy. (Knaus, Draper et al. 1985) 
The APACHE-II system was developed as a general measure of disease severity and not 
specifically as a tool for describing acute pancreatitis. Each physiologic parameter is 
weighted from 0 to 4, and an aggregate score is tabulated (Knaus, Draper et al. 1985). Unlike 
the Ranson and Glasgow criteria, APACHE-II can provide a valid prediction of mild 
pancreatitis on admission. The APACHE-II is valid for repeated measures throughout 
hospitalization and it represents a universal measurement of disease severity, obviating the 
need for a separate score for acute pancreatitis. The APACHE II performs very well as a 
prognostic tool, with sensitivity and specificity rates of 75% and 92% respectively (Wilson et 
al. 1990).  
3.2.5 Bedside Index for Severity in Acute Pancreatitis (BISAP) 
A newer prognostic scoring system, the Bedside Index for Severity in Acute Pancreatitis 
(BISAP) has been proposed as an accurate method for early identification of patients at risk 
for in-hospital mortality (Wu, Johannes et al. 2008). The BISAP combines findings of 
physical examination, vital signs, routine laboratory data, and imaging studies to derive a 
five-point score (Wu, Johannes et al. 2008).  
Individual Components of the BISAP Scoring System 
BUN > 25mg/dl 
Impaired mental status (Glasgow Coma Scale Score < 15) 
Age > 60 years 
Pleural effusion detected on imaging 
SIRS, ≥ 2 or more of the following: 
Temperature <36°C or >38°C 
Respiratory Rate >20 breaths/min or PaCO2 <32 mmHg 
Pulse > 90 beats/min 
WBC count > 12,000 or <4,000 cells/mm3 or >10% immature neutrophils (bands 
Adapted from Gut 57(12): 1698-1703 (Wu, Johannes et al. 2008) 
Table 6. BISAP Scoring System 
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The BISAP uses five ordinal points: urea nitrogen (BUN) >25 mg/dl, impaired mental status 
as defined by evidence of disorientation or alteration in mental status, presence of Systemic 
Inflammatory Response Syndrome (SIRS), age > 60 years, and the presence or absence of 
pleural effusions (Singh, Wu et al. 2009).  
SIRS is defined by the presence of ≥ 2 of the following criteria:  
Pulse >90 beats/min, respirations >20/min or PaCO2 <32 mmHg, temperature >38°C of 
<36°C, WBC count > 12,000 or <4,000 cells/mm3 or >10% immature neutrophils (bands). 
The presence of each variable contributes one point to a total 5-point score, and is obtained 
within 24 hours of admission; there is no requirement for additional computation, and the 
assessment of mental status is the only subjective parameter involved. It should be noted, 
however, that the SIRS criterion is a composite parameter that involves four separate but 
related criteria. Essentially, the BISAP is an eight-variable system cumulatively applied to 
calculate five points. (Wu, Johannes et al. 2008) 
Studies have demonstrated that the BISAP score can predict mortality risk (Wu, Johannes et 
al. 2008). Studies have demonstrated that a BISAP score ≥ 3 is associated with higher 
mortality when compared to scores < 3; high specificity and negative predictive values were 
observed using these ordinal values (Wu, Johannes et al. 2008). Furthermore, it has been 
shown that BISAP scores ≥ 3 predict the development of organ failure, persistent organ 
failure, and the evolution of pancreatic necrosis. (Singh, Wu et al. 2009) 
The key advantages of the BISAP include its relative ease of use and application of 
parameters that are commonly obtained either at presentation or within 24 hours of 
presentation (Wu, Johannes et al. 2008). The score appears generalizable, having been 
initially formulated and validated using a large number of patients across 389 hospitals, 
reflecting a broad spectrum of health-care delivery. (Singh, Wu et al. 2009) 
The BISAP score cannot readily distinguish transient organ dysfunction from more 
persistent organ dysfunction at 24 hours (sensitivity of 38%, specificity 92%, PPV 58%, and 
NPV 84%), an important clinical distinction since the latter group suffers the majority of 
morbidity and mortality in acute pancreatitis (Zimmerman et al. 1994). The BISAP score 
may prove more useful in the triage of patients to levels of care intensity on initial 
evaluation rather than being used to predict the development of persistent organ failure and 
its consequences. (Papachristou, Muddana et al. 2010) 
In summary, the BISAP score is a reliable prognostic tool enabling classification of patients 
with acute pancreatitis into mild or severe groups, and its components are clinically relevant 
and easy to obtain. It is important to recognize that an inherent limitation of all such scoring 
systems is their conversion of continuous variables into binary values of equal weight and 
thus fail to capture synergistic or multiplicative effects based on interactions of 
interdependent systems.  
3.3 Imaging based risk models 
3.3.1 Ultrasonography 
Ultrasonography (US) may be useful in the early assessment of acute pancreatitis to evaluate 
the biliary system for the presence of gallstones or common bile ductal stones. However, US 
www.intechopen.com
 
Acute Pancreatitis: Presentation and Risk Assessment 
 
113 
use is often technically limited to applications in the early staging of acute pancreatitis due 
to the presence of overlying bowel gas secondary to paralytic intestinal ileus. In aggregate, 
abnormal US findings are seen in 33-90% of patients with acute pancreatitis; a diffusely 
enlarged and hypoechoic gland is consistent with interstitial edema, while extrapancreatic 
fluid collections (e.g., lesser sac, anterior pararenal space) can be detected in patients with 
severe disease. (Balthazar 2002) 
3.3.2 Computed Tomography (CT) 
Most of the clinical and laboratory parameters discussed thus far are applied to evaluate the 
systemic effects of pancreatitis, and only indirectly infer the presence and degree of 
pancreatic damage. The use of Computed Tomography (CT) in acute pancreatitis has 
increased in the last decade as it offers improved anatomic visualization, direct assessment 
of the extent of parenchymal injury, and identification of local complications (Dervenis et al. 
1999). The CT Severity Index (CTSI) derived by Balthazar et al. has become the standard 
objective assessment for the description of CT findings in acute pancreatitis. (Balthazar 2002)  
The first described CT grading index was based on radiographic images obtained without 
the addition of intravenous (IV) contrast (Hill et al. 1982). Using the scoring system, it was 
demonstrated that patients with high grade pancreatic damage (grades D or E) had a 
mortality rate of 14% and a morbidity rate of 54%, as compared with no mortality and a 
morbidity rate of only 4% in lesser affected patients (groups A, B or C.) Due to the lack of IV 
contrast, its main drawback was an inability to reliably depict pancreatic necrosis (Balthazar, 
Robinson et al. 1990).  
A major significant improvement has been achieved in early CT grading systems with the 
introduction of an incremental contrast bolus CT technique (Kivisaari et al. 1983). Contrast-
enhanced CT has been used effectively to directly characterize and quantify pancreatic 
parenchymal injury. Investigators have shown that the attenuation values of pancreatic 
parenchyma during an intravenous contrast bolus study can be used as an indicator of 
pancreatic necrosis and as a predictor of disease severity (Dervenis et al. 1999).  
Patients with mild interstitial pancreatitis have an intact but vasodilated capillary network 
and therefore exhibit uniform enhancement of the pancreatic gland (Balthazar 2002). To the 
contrary, areas of diminished or no enhancement are indicative of decreased blood flow and 
reveal pancreatic zones of ischemia or necrosis (Balthazar 2002). An excellent correlation has 
been documented between necrosis, length of hospitalization, development of 
complications, and death. Furthermore, the extent of pancreatic necrosis has also been 
proven to be of clinical importance with prognostic and therapeutic implications (Vitellas et 
al. 1999). Studies have shown that patients with less than 30% necrosis exhibited no 
mortality and a 48% morbidity rate, while larger areas of necrosis (30-50% and >50%) were 
associated with morbidity rates of 75-100% and mortality rates of 11-25% (Balthazar, 
Robinson et al. 1990). 
The CT Severity Index (CTSI) was designed to improve the early prognostic value of CT in 
cases of acute pancreatitis and is based on IV contrast-enhanced imaging (Balthazar, 
Robinson et al. 1990). The grading and allocation of points takes into consideration the CT 
grade as well as the extent of necrosis and is illustrated in the table below. It has been 
www.intechopen.com
 
Pancreatitis – Treatment and Complications 
 
114 
demonstrated that a statistically significant correlation exists between morbidity and 
mortality and the CTSI score (Balthazar, Robinson et al. 1990). Studies have shown that 
patients with a severity index of 0 or 1 exhibit a 0% mortality rate and no morbidity, while 
patients with a severity index of 2 had no mortality and a 4% morbidity rate (Balthazar, 
Robinson et al. 1990). In contrast, a severity index of 7-10 yields a 17% mortality rate and a 
92% complication rate. (Balthazar, Robinson et al. 1990) In a clinical study comparing BISAP, 
Ranson criteria, APACHE-II, and CTSI, CTSI was the most accurate in predicting pancreatic 
necrosis. (Papachristou, Muddana et al. 2010) 
CT grade Grade
Points
Necrosis  
(in percentage)
Necrosis 
Points 
CT severity 
indexb 
Normal ( A )  0 0 0 0 
Focal, diffuse enlargement, contour 
irregularity, inhomogenous attenuation 
( B ) 
1 0 0 1 
B + peripancreatic haziness/strand 
densities ( C ) 
2 < 30 2 4 
B + C + one ill-defined peripancreatic 
fluid collection ( D ) 
3 30 - 50 4 7 
B + C + two ill-defined peripancreatic 
fluid collections ( E ) 
4 < 50 6 10 
a Balthazar 
b Grade points are added to points assigned for percentage of necrosis. 
Table 7. Computed Tomography Severity Indexa 
Adapted from Eur J Gastroenterol Hepatol 23(7): 541-551 (Brisinda, Vanella et al. 2011) of 
presentation may show only equivocal findings of pancreatitis, and that CT scans 
obtained 3 days after clinical onset yield higher accuracy in the depiction of pancreatic 
necrosis (Vitellas et al. 1999). Thus, it is recommended that when the clinical diagnosis of 
pancreatitis is in doubt, an initial early CT be used to confirm the clinical suspicion or to 
help detect alternative acute abdominal conditions that mimic acute pancreatitis. For 
staging, however, more reliable results are obtained with the use of intravenous bolus 
contrast-enhanced CT performed 48-72 hours after the onset of an acute attack of 
pancreatitis. (Balthazar 2002) 
It appears that the CTSI is an anatomically oriented scoring system that aids in identifying 
local complications from pancreatitis, while clinical scores, such as the APACHE-II, may be 
superior for predicting associated organ failure and systemic complications (Lankisch et al. 
2000). In patients with predicted severe disease or those manifesting a severe clinical course 
within the first 48 hours of presentation, the CTSI appears superior to other scoring systems 
in predicting overall pancreatitis severity and pancreatic necrosis. (Chatzicostas, 
Roussomoustakaki et al. 2003) At present, it appears that clinical scores are the best way to 
stratify the immediate management of acute pancreatitis, particularly the requirement for 
intensive care, and that the value of CT is greater in evaluating intermediate term 
management. (Alhajeri and Erwin 2008)  
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3.3.3 Magnetic Resonance Imaging (MRI) 
The development of high field strength magnetic resonance imaging (MRI), rapid gradient-
echo breath hold techniques, and fat suppression methodologies has made MR imaging an 
excellent alternative imaging modality to aid in the evaluation of patients with acute 
pancreatitis (Lecesne et al. 1999). It is particularly useful in patients who cannot receive 
iodinated contrast material due to allergic reactions or renal insufficiency. Gadolinium-
enhanced T1 weighted gradient-echo MR images can depict pancreatic necrosis as areas of 
non-enhanced parenchyma (Fulcher, Turner 1999). Fat-suppression images are also helpful 
in defining subtle, diffuse, or focal parenchymal abnormalities. T2 weighted images can 
accurately depict fluid collections, pseudocysts, and areas of haemorrhage. (Balthazar 2002) 
4. Conclusion  
Acute pancreatitis is a dynamic entity with varying degrees of severity. Most episodes of 
acute pancreatitis are generally mild, but up to a third of cases may progress to severe 
pancreatitis. This is associated with a significant increase in associated mortality and 
complications. The key to effectively managing the patient with an episode of acute 
pancreatitis is early identification and diagnosis, followed by an appropriate assessment of 
severity. Appropriate evaluation of severity and prognosis is of great help in aiding the 
clinician in administering appropriate care. The clinician needs to be able to determine 
which patients will benefit from invasive intervention or transfer to a critical care  unit, with 
the availability of its attendant intensive laboratory and cardiorespiratory monitoring.  
A variety of prognostication systems for acute pancreatitis have been developed over the 
years to better categorize disease severity and predict clinical outcomes. There are three 
commonly employed types of predictors of the severity of acute pancreatitis: individual 
biological markers, multi-parameter scorings systems, and imaging-based systems. Within 
each category there are several individual systems, each with unique advantages and 
disadvantages. Given the currently available tools, the majority of patients presenting with 
acute pancreatitis will benefit from a rational and informed combination of these 
complimentary but distinct systems. In an era where intensive and invasive techniques are 
available to manage the local and systemic complications of pancreatitis, the ability to 
appropriately identify patients who will benefit from these interventions in a timely fashion 
is an important adjunct to their care. 
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